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Sterile inflammation (SI) is an essential process in response to snakebite and injury. The venom induced 
pathophysiological response to sterile inflammation results into many harmful and deleterious effects 
that ultimately leads to death. the available treatment for snakebite is antiserum which does not 
provide enough protection against venom-induced pathophysiological changes like haemorrhage, 
necrosis, nephrotoxicity and often develop hypersensitive reactions. in order to overcome these 
hindrances, scientists around the globe are searching for an alternative therapy to provide better 
treatment to the snake envenomation patients. in the present study tio2 (Titanium dioxide)-NPs 
(Nanoparticles) has been assessed for antisnake venom activity and its potential to be used as an 
antidote. in this study, the synthesis of tio2-nps arrays has been demonstrated on p-type Silicon 
Si < 100 > substrate (∼30 ohm-cm) and the surface topography has been detected by Field-emission 
scanning electron microscopy (FESEM). The TiO2-nps successfully neutralized the Daboia russelii venom 
(DRV) and Naja kaouthia venom (NKV)-induced lethal activity. Viper venom induced haemorrhagic, 
coagulant and anticoagulant activities were effectively neutralized both in in-vitro and in vivo studies. 
The cobra and viper venoms-induced sterile inflammatory molecules (IL-6, HMGB1, HSP70, HSP90, 
S100B and vWF) were effectively neutralised by the TiO2-nps in experimental animals.
Biomedical therapy and diagnostics are getting more prominent with the utilization of nanotechnology concept1. 
The aim of using a nano-medicine is to improve the bio-distribution of therapeutic agent and to allow its accu-
mulation on the target site2. Different types of nano-medicine have been evaluated in recent years, f.e., liposomes, 
polymers, micelles and antibodies. Several evidences also indicate the ability of these nano-sized carrier materials 
to improve the balance between the efficacy and the toxicity of therapeutic interventions.
Today, nano-scale research has been emerged as important players in the field of pharmacology and biotech-
nology. Except few nanoparticles and quantum dots, most of them are toxic in nature and are not applicable for 
medical or therapeutic applications3. TiO2 has a wide spectrum of properties that varies with different techniques 
used for its synthesis4 and has applications in the field of biomedical research and treatment such as anti-tumour 
therapy5,6, manufacturing of bio-products7 etc. Ubiquitous applications and better results of TiO2-NPs, makes 
them a potential candidate for biomedical research8. In the present study, the synthesis of TiO2-NPs arrays has 
been demonstrated on p-type Silicon Si < 100 > substrate (∼30 ohm-cm) and the surface topography has been 
detected by Field-emission scanning electron microscopy (FESEM). The size of the deposited TiO2-NPs is maxi-
mum in the range of 5–6 nm. The Energy-Dispersive X-ray (EDX) mapping of FESEM image showed the presence 
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of Titanium (Ti), Oxygen (O2) and Si (Substrate) in the sample. Raman analysis confirms the crystalline nature of 
TiO2-NPs with Anatase and Rutile modes.
Present day lifestyle increases the risk of several deadly diseases including cardiovascular disorder, diabe-
tes, cancer, etc. In these cases early detection and treatment can decrease the mortality rates. Apart from these 
lifestyle related diseases, some clinical conditions such as snake envenomation also pose a major public health 
challenge across the world. About 5.4 million annual snakebite cases are reported globally and more than 100,000 
people die each year as a result of snakebites of which more than 50,000 deaths occur in India alone9. Majority of 
deaths reported are particularly from rural and agriculturally active areas. WHO has also declared snakebite as a 
‘neglected tropical disease’ and is now a global health priority9–12. Antiserum is the only choice to treat snakebite 
patients, which again is not always effective against venom-induced haemorrhage, necrosis, nephrotoxicity and 
often develop hypersensitive reaction13–17. Antiserum development in animal is time consuming and needs cold 
chain management. Therefore, there is a need to develop suitable therapeutic agent for the treatment of snakebite. 
Now-a-days use of nanoparticles are quite popular and frequently used as a drug-delivery vehicles2,18. TiO2 is one 
such promising material because of its wide spectrum properties that varies with different techniques used for its 
synthesis3 and has been reported for various applications in the field of biomedical research4–6.
Sterile inflammation is an essential process in response to snakebite and injury. The pathophysiological 
response to sterile inflammation results into many harmful and deleterious effects that ultimately lead to death. 
The harmful effects of snake envenomation are haemorrhage, necrosis, renal failure, cardiotoxicity, neurotox-
icity, myotoxicity and hematoxicity. These deleterious effects could be due to the increased formation of sterile 
molecules: HMGB1, HSPs, S100B and IL6. HMGB1 which has recently been drawn much attention because of 
its binding ability to cell signalling receptors like RAGE, TLR2, TLR4 and TLR9 receptors. These receptors have 
major role in the initiation of inflammatory response and they also participate in development and progression 
of haemorrhage, necrosis, and cell death. Similar pathophysiological changes were also observed in case of snake 
envenomation. Therefore, in this paper we have shown the expression of the sterile inflammatory marker mole-
cules developed in response to snakebite in experimental animals and its neutralization by TiO2.
Materials
chemicals. All chemical used in this study were of analytical grade. The solvents used were prepared in dis-
tilled water.Anti-Hsp70 antibody, Anti-Hsp90 antibody, Anti-IL-6 antibody, Anti-Von Willebrand Factor anti-
body, Anti-S100 beta antibody, Anti-HMGB1 antibody-ChIP Grade were purchased from Abcam (Cambridge, 
MA, USA); and O-Phenylenediamine dihydrochloride and bovine serum albumin were purchased from Sigma 
Aldrich (St. Louis, MO, USA). MaxiSorp flat-bottom 96-well plates were purchased from Nunc GmbH & Co, 
Langenselbold, Germany.
Methods
Animals. Male Swiss albino mice (18–20 g) used in this study was obtained from the animal house of Jamia 
Hamdard (Hamdard University), New Delhi. Guidelines of the Institutional Animal Ethical Committee has been 
followed for the care and handling of animals. All mice were housed five/cages and fed standard laboratory diet 
and water ad libitum with 12-h dark/light cycles at constant temperature of 25 ± 2 °C. ‘Principles of laboratory ani-
mal care’ (NIH publication No. 85-23, revised in 1985) as well as Indian laws on ‘Protection of Animals’ have been 
followed for all the animal experiments under the provision of authorized investigators. Experiments involving 
the use of mice were approved by the Committee for the Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA) of the Jamia Hamdard (Deemed University), New Delhi (permission #173/GO/Re/S/2000/
CPCSEA). Experiments involving animals meet the International Guiding Principles for Biomedical Research 
Involving Animals (CIOMS).
preparation of nanoparticles. The GLAD technique was carried out to deposit TiO2 (High purity) 
(99.99%, MTI, USA) NPs of 5 nm range inside the electron beam chamber (Hind High Vacuum Co. (p) Ltd., 
15F6) on p-type Silicon Si <100> substrate (∼30 ohm-cm) at a base pressure of ~2 × 10−5 mbar19. The substrates 
were rotated azimuthally with constant speed of 460 rpm at an orientation of 85° with respect to the perpendicular 
line between the metal source and the planar substrate holder20. A low deposition rate of 1.2 Å/s was kept con-
stant, which was monitored by a quartz crystal. Then the grown TiO2-NPs were ultrasonicated in electron grade 
acetone to make a liquid solution. The surface morphology of randomly placed TiO2-NPs over n-type Si substrate 
of probably 5 nm was observed using an Atomic Force Microscope (BrukerInnova).
preparation of venoms. Lyophilized snake venom from Daboia russelii (Viper), and Naja kaouthia 
(Cobra) were obtained from Calcutta Snake Park (Kolkata, India) and was preserved in desiccators at 4 °C in an 
amber-coloured glass vial until further use. The snake venom was dissolved in 0.9% saline and centrifuged at 2000 
rpm for 10 min. The supernatant was used as venom and kept at 4 °C and used within three month. The venom 
concentration was expressed in terms of dry weight (mg/ml, stock venom solution)21.
Venom inhibiting activity. To determine the venom inhibiting activity of the nanoparticles, following 
pharmacological experiments were performed:
Inhibition of venom lethal effect. Snake venom toxicity assessment was done by intravenous (i.v) injection of 
venom prepared in 0.2 mL physiological saline at different concentration in male albino mice weighing18–20 g22,23. 
Assessment of in vitro antagonism was done by mixing different concentrations of venom (2.2–22 µg) with a fixed 
amount of TiO2-NPs, the mixture incubated at 37 °C for 1 hour, and then centrifuged at 2000 rpm for 10 minutes. 
The supernatant was injected intravenously (i.v) into male albino mice, six mice per dose. The median lethal dose 
(MLD50) was calculated 24 hours after injection of the venom-TiO2-NPs mixture. Lethal toxicity was also assessed 
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by subcutaneous (s.c) injection of various doses of venom. The neutralizing potency of TiO2-NPs was assessed 
by injection (s.c) of venom (45–225 µg) into groups of six mice followed by immediate injection of fixed dose of 
TiO2-NPs (5 ng) intravenously24.
Inhibition of venom haemorrhagic activity. The minimum haemorrhagic dose (MHD) of venom which when 
administered into mice causes development of haemorrhagic lesion of 10 mm diameter within 24 hours23. This 
lesion was measured and the estimation of neutralization of the haemorrhagic activity was done by mixing a 
fixed amount of TiO2-NPs (2 ng) with different amounts of venom (5–25 µg). The mixture of TiO2-NPs- venom 
was incubated at 37 °C for 1 hour, then spin at 2000 rpm for 10 min and finally 0.1 ml of supernatant taken were 
injected intradermally (i.d)25. After 24 hours haemorrhagic lesion was estimated. To assess the anti-haemorrhagic 
activity of venom in vivo, various amount of venom (5–15 µg) were injected (i.d) followed by the TiO2-NPs (5 ng, 
intravenously) and the haemorrhagic lesion measured after 24 hours.
Inhibition of venom necrotic activity. To assess the in vitro anti-necrosis effect of TiO2-NPs, various concentra-
tion of venom (5–25 µg) were incubated with fixed amount of TiO2-NPs and administered intradermally (i.d) into 
mice. The necrotic lesion was estimated after 48 hours. In in vivo study, the venom (i.d) (5–15 µg) was injected 
followed by injection (i.v) of TiO2-NPs and observed after 48 hours.
Inhibition of venom defibrinogenating activity. Defibrinogenating activity of venoms or toxins is expressed as 
the minimum defibrinogenating dose (MDD). MDD of DRV is defined as the minimum amount of venom which 
when injected (intravenously) into mice causes incoagulable blood 1 hour later. Neutralization of this activity 
was estimated by mixing different amount of venom (2.5–12.5 µg) with fixed amounts of TiO2-NPs, incubating 
at 37 °C for 1 hour and centrifugation. The supernatant was injected (i.v) into albino mice (18–20 g) as described 
above (in vitro). For in vivo studies, the MDD of venom was injected (i.v) followed by the TiO2-NPs (i.v) and the 
nature of the blood observed after 1 hour26.
Inhibition of venom PLA2 effect. For carrying out the PLA2 inhibition activity, 2 ml of egg yolk suspension, 0.2 ml 
of test material (venom, TiO2-NPs and Venom + TiO2-NPs) were mixed in the different test tube and kept for 
1 hour incubation at 37 °C. The test tube containing test materials were kept on a water bath and the time required 
for coagulation was recorded. A blank was run with normal saline in place of test material. One unit enzyme 
activity was defined as the amount of venom, which increased the coagulation time of the egg yolk control by one 
minute27. Estimation of neutralization of the enzyme activity, was done when fixed amount of TiO2-NPs (2 ng) 
were mixed with different amount of viper venom (2–10 μg) and the mixture was incubated for 1 hour at 37 °C. 
Figure 1. Structural behaviour of TiO2-NPs. (A) Top view FESEM images of nano-sized TiO2 particles. (B) 
Element mapping of the sample. (C) Particle histogram of Image 1(A). (D) Raman spectrum of TiO2 -NPs.
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Centrifuged at 2000 rpm for 10 minutes, supernatant was tested in a total of 0.2 ml for the enzyme neutralization 
activity.
Inhibition of venom-induced mouse paw oedema. The minimum oedematic dose (MOD) of venom/carrageenan 
is defined as the least amount of venom/carrageenan which when injected into male albino mice produced 
inflammation (oedema) in the paw. Non-fasted male albino mice (18–20 g) were treated with different doses 
of venom, carrageenan and TiO2-NPs. To assess the anti-inflammatory activity of TiO2-NPs various amount of 
venom/carrageenan (in 0.01 ml) were injected (intraplantar) followed by the intraperitoneal (i.p) injection of 
TiO2-NPs (250 ng/kg) and anti-inflammatory activity was measured. For control, equal amounts of saline were 
injected (intraplantar). The oedematogenic response was evaluated by the use of a screw gauge at given time 
intervals. Oedema was reported as the percentage difference between the values obtained from the injected paw 
with the carrageenan, venom, venom + TiO2-NPs, carrageenan + TiO2-NPs and saline, as described by Trebien 
and Calixto24,28.
Figure 2. Viper (Daboia russelii) venom (VRV) induced inflammatory changes in experimental animals. 
Results expressed as mean ± SEM (n = 6). Results obtained are significantly different from control group 
(*P < 0.05) and Daboia russelii venom (#P < 0.05).
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Inhibition of Sterile inflammatory Markers. Different pro-inflammatory markers such as heat shock proteins 
(HSP70 and HSP90), high mobility group box 1 (HMGB1), interleukin 6 (IL-6), von Willbrand factor(vWF), 
and S100 calcium-binding protein B (S100B) was done by ELISA as described by Engvall et al.29. Briefly, 50 μg of 
proteins were used with bicarbonate coating buffer to coat the wells in 96-well plates and incubated over night 
at 4 °C. Nonspecific binding was blocked with 5% BSA and then the samples were washed with PBST (0.05% 
Tween-20) and incubated for 3 hours with respective primary antibodies (against Hsp70; Hsp90; HMGB1); IL-6; 
vWF; S100b (1:1000). Next, the wells were washed and incubated with HRP conjugated secondary antibodies for 
1 hour, and then washed with PBST and incubated with OPD substrate solution. The reaction was terminated by 
adding H2SO4 (1 N) and absorbance was measured at 450 nm. Using similar methods, a standard ELISA curve for 
absorbance versus specific antigen concentration was constructed using respective recombinant proteins.
Results
topographic image of tio2-nps. In case of GLAD, the TiO2-NPs are formed due to the atomic shadow-
ing effect on the arbitrarily deposited seeds. The diffusivity of the landed atoms on the substrate depends on the 
rate of evaporation. A lower evaporation rate of the material will enable the landed atoms to diffuse for longer 
distances before they get impinged by next arriving atoms. This can lead to an increase in the capture radius of the 















Venom nano-particles incubated 37 °C, 60 min and injected i.v
TiO2 (2) 11 5 6 2.1
Control
Venom injected (s.c) ** followed immediately by TiO2 (i.v)
TiO2 (5) 45 1.0 10 2.1
Table 1. Inhibition of lethal action of Viper and Cobra venom by TiO2-NPs. Results are expressed as 
mean of six observations. **Duration of deaths time following venom exposure (venom control animal): 
DRV (1 Median Lethal Dose) = 13.24 ± 0.30 hours; Cobra (Naja kaouthia) venom (1 Median Lethal 
Dose) = 6.20 ± 0.30 hours.
TiO2 (ng) Viper Venom μg) Fold of neutralization (In terms of MHD)
Venom-TiO2 nanoparticles incubated 37 °C, 60 min and injected i.d
TiO2 (2) 20 4
Venom injected (i.d) followed immediately by TiO2 (i.v)
TiO2 (5) 10 2
Table 2. Inhibition of haemorrhagic action of Viper venom by TiO2-NPs. *Results are expressed as mean of six 
observations. i.d = intra-dermal. i.v = intra-venous.
TiO2 (ng) Viper Venom (μg) Fold of neutralization (In terms of MDD)
Venom-nanoparticles incubated 37 °C, 60 min. and injected (i.v)
TiO2 (2) 5.0 2.0
Venom injected (i.v) followed immediately by TiO2
TiO2 (5) 3.5 1.5
Table 3. Inhibition of defibrinogenating activity of Viper venom by TiO2-NPs. *Results are expressed as mean 
of 6 observations. MDD = Minimum Defibrinogenating Dose = 2.5 μg.
Group Viper Venom (μg) Fold of neutralization (In terms of unit)
Control (only Venom)
Viper (2 µg) 2(1) 1
Venom-NPs incubated 37 °C, 60 min then added to egg yolk suspension
TiO2 (2 ng) 10 5
Table 4. Inhibition of Phospholipase A2 activity of Viper venom by TiO2-NPs. Results are expressed as mean 
of ten observations. 1 unit = one unit of enzyme activity of DRV was defined as the amount of venom which 
increased the coagulation time of egg yolk by one minute.
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on p-type Si substrate prepared at 85° and 460 rpm azimuthal rotation to the sample, the images were captured by 
FESEM, keeping the gun vacuum on 2.18 e-009 mBar. The EDX element mapping reveals Titanium (Ti, brown 
color) and Oxygen (O, green color) are present in the sample shown in Fig. 1B. Figure 1C projects the particle 
counts histogram of FEG: SEM image 1 A, the grown particles were in the range of 1–14 nm, where maximum 
number of NPs had a count of 5–6 nm. The Raman spectra processing of TiO2 samples shows that the grown 
nanoparticles are having two Anatase and Rutile modes30 (Fig. 1D).
Raman analysis. Raman spectroscopy is a flexible and most authenticated technique used for ubiquitous 
sectors. It is a very prominent tool for nano-biomedical studies and also helpful in the analysis of food and phar-
maceutical non-materials. It has a great impact on drug analysis due to its simplicity in minimal sample handling 
and the significant differences in scattering strength between packaging materials tablet excipients, and active 
drug components31. Figure 1D shows the dependence of the Raman scattering intensity on the incident laser 
wavelength (laser excitation 532 nm). We have noticed that our prepared TiO2-NPs have crystalline nature and 
also have some characteristic peaks.
properties of snake venoms and tio2-nps. LD50 of DRV was found to be 2.2 μg intravenously and 45 μg 
when injected subcutaneously in mice (18–20 g); whereas NKV was 2.8 μg intravenously and 4.61 μg subcutane-
ously. The MHD/MND was 5 μg per animal (18–20 g) of DRV. MDD was 2.5 μg per animal (18–20 g) of DRV. The 
concentration of viper and cobra venoms in terms of protein were found to be 91.5% and 95% respectively. The 
TiO2-NPs [up to 25 ng per animal (18–20 g); i.v] did not produce any lethal effect up to 48 hours of observations22.
Lethal activity. In in-vitro study, viper and cobra venoms (1–10 LD50) were incubated with TiO2 -NPs (2 ng) 
and gave protection against venom-induced lethality. In in vivo study, cobra venom (1–5 LD50) was injected (s.c) 
into male albino mice followed by TiO2-NPs (5 ng/mouse, i.v). Viper and Cobra venom-induced lethality was 
significantly antagonized by TiO2-NPs as compared with the control animal (venom only) (Table 1). The ED50 of 
the TiO2-NPs was observed as 2 ng in vitro and 4 ng in in vivo respectively against viper venom (Table 1).
Haemorrhagic and necrotic activity. In in-vitro study, Viper venom (20 µg) incubated with TiO2 (2 ng) 
and injected 0.1 ml (i.d) into mice. It showed protection against venom induced haemorrhagic activity (Table 2). 
In in-vivo study, venom (10 µg) injected (i.d) into mice followed by the injection (i.v) of TiO2-NPs (5 ng) gave 
protection against venom-induced haemorrhagic activity. The degree of protection in in-vivo was less than that 
of in-vitro studies.
Defibrinogenation activity. The TiO2-NPs effectively antagonized the viper venom-induced defibrinogen-
ating activity. In in-vitro study, the TiO2-NPs (2 ng) gave protection up to 2 MDD (5 µg) against venom-induced 
defibrinogenation. In in-vivo study, venom-induced defibrinogenation was antagonised by TiO2-NPs. The fold of 
protection was always higher in in vitro studies (Table 3).
Neutralisation of Venom Phospholipase A2 (PLA2) activity. Egg yolk coagulation method was per-
formed to assess the PLA2 activity of viper venom. 1 unit of venom activity which increased the coagulation time 
by 1 minute was found to be 2 μg (control 0.9% saline, coagulation time was found to be 45 ± 1.16 seconds). The 
TiO2-NPs were tested for Phospholipase A2 activity by incubating with different amount of venom (10 μg). The 
venom PLA2 was effectively neutralized by the TiO2-NPs (Table 4).
Mouse paw oedema. The assessment of anti-inflammatory activity of the TiO2-NPs was done by mouse paw 
oedema. Mouse paw oedema was induced by venom, attained its peak at 1 hour of observation. The TiO2-NPs at a 
dose of 5 ng/mouse (i.p) was found to produce significant inhibition of venom-induced inflammation. Inhibition 





1 hour 2 hour 3 hour 4 hour
Control (0.9% saline)
Viper venom 001(1) 105.3 ± 5.8 87.5 ± 07.7 83.74 ± 5.9 78.43 ± 6.5
Carrageenan 300(1) 054.4 ± 7.2 47.9 ± 11.3 35.20 ± 7.6 34.60 ± 5.3
Inhibition studies (Carrageenan injected 300(1) into intraplantar surface followed immediately by TiO2-NPs)
TiO2-NPs (250 ng/kg) 5(5) 47.5 ± 1.7 51.3 ± 2.5 52.0 ± 1.2 52.8 ± 2.9
Aspirin (10 mg/kg) 5(5) 43.9 ± 0.9 42.8 ± 1.2 42.2 ± 1.7 42.1 ± 0.8
Indomethacin (10 mg/kg) 5(5) 40.8 ± 1.9 40.3 ± 1.3 40.1 ± 0.5 39.9 ± 2.1
Inhibition studies (Carrageenan injected 300(1) intraplantar surface followed immediately by TiO2-NPs)
TiO2-NPs (250 ng/kg) 600(2) 46.0 ± 1.8 49.6 ± 2.4 48.2 ± 1.6 48.0 ± 3.2
Aspirin (10 mg/kg) 600(2) 37.6 ± 2.7 42.6 ± 3.2 39.7 ± 2.7 40.1 ± 3.1
Indomethacin (10 mg/kg) 600(2) 35.1 ± 1.5 35.7 ± 2.8 35.3 ± 2.5 35.0 ± 1.4
Table 5. Viper venom induced inflammation and inhibition by TiO2-NPs. Venom and carrageenan were 
injected intraplantar in the foot pads. Drugs were administered (i.p) immediately after envenomation at 0 hour.
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aspirin (42.8 ± 1.2%) and indomethacin (40.3 ± 1.3%). Carrageenan (300 µg in 0.01 ml) injection produced sig-
nificant inflammation in mouse paws. Pre-treatment with TiO2-NPs (5 mg/kg, i.p) before carrageenan injection 
produced a significant reduction in oedema (Table 5).
Sterile inflammatory markers. The sterile inflammatory markers HMGB1, HSP70, HSP90, IL-6, S-100B 
and vWF were found to increase in Viper and Cobra venoms treated mouse while treatment with TiO2-NPs sig-
nificantly reduced confirming the anti-inflammatory effects of TiO2-NPs (Figs 2 and 3).
Discussion
Injury and death due to snake bite is major health hazards in tropical and subtropical countries. In India more 
than 250 species of snakes are found, out of which 50 are venomous. Cobra and viper are the common snakes 
found throughout India32–34. The majority of death occurs due to the bites of these snakes. Snake envenomation is 
characterized by severe damage caused by the toxic action of venom components. The venom contains multiple 
components that induce haemorrhage, necrosis, inflammation, nephrotoxicity, cardiotoxicity, hematoxicity and 
often leads to death35,36. Viper and cobra venom contains major parts of Phospholipase A2 (PLA2) and metallo-
proteinase. Viper venom is a rich source of PLA2 enzyme that leads to many pathophysiological disturbances in 
Figure 3. Cobra (Naja kaouthia) venom (NKV) induced inflammatory changes in experimental animals. 
Results expressed as mean ± SEM (n = 6). Results obtained are significantly different from control group 
(*P < 0.05) and Naja kaouthia venom (#P < 0.05).
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the victims34. These components directly damage the micro-vessels, with consequent increase in haemorrhage 
and oedema34. The inflammatory effect induced by viper envenomation is due to the presence of PLA2 enzyme 
in venom34–37. The inflammatory effects induced by PLA2 in response to cobra and viper venoms are primar-
ily related to the action of this enzyme on the membrane phospholipids and the release of eicosanoid precur-
sors25,38–42. In present work, we characterized the oedematogenic, haemorrhagic, lethal and anti-inflammatory 
effects induced by the viper venom and its neutralization by TiO2-NPs (Fig. 4). Nanomedicine is a rapidly evolv-
ing field that provide enhanced diagnostic imaging and treatment of diseases known as theranostic. On account 
of improved health care, theranostic approaches are employed to make drug delivery more efficient and target 
specific. Theranostic nanomedicine can also be used for different purposes like non-invasive assessment of the 
pharmacokinetics, bio-distribution and the target site localization of conjugated or entrapped active agents43,44. 
Therefore TiO2-NPs is considered as a suitable target for medicine delivery as well as for detection of target cells 
due to its high fluorescence property under the excitation of normal white light in in vitro condition.
In this study, we have shown that TiO2-NPs are effective agent that may be used as a treatment in snake 
venom induced pathophysiological changes. TiO2 -NP arrays have been fabricated on p-type Si substrate using 
a cost effective (GLAD, PVD) technique. The surface topography revealed that the average size of TiO2-NPs 
is in nano-metric range. The element mapping of FESEM image indicates the presence of Titanium (Ti) and 
Oxygen (O) in the sample. The stability of TiO2-NPs synthethised by glancing angle deposition technique was 
calculated by its zeta potential. The continuous SAED analysis of TiO2-NPs reveals that particles are having crys-
talline behaviour with fine stability. So far, we have seen that TiO2-NPs effectively neutralize the viper and cobra 
venom-induced lethal activities both in in vitro and in vivo studies. TiO2-NPs also effectively neutralized the viper 
venom induced haemorrhagic activity in experimental animals. The fold of venom induced lethal and haemor-
rhagic activity was always found to be higher in in vitro than in vivo studies. The TiO2-NPs were also found to be 
more effective in viper venom induced pathophysiological changes than the cobra venom. The exact mechanism 
of action is still unclear. Among the several, one of the consequences of snake envenomation is increased DAMP 
molecules. Here, we have shown for the first time that the sterile inflammatory markers like IL-6, HSP, vWF, 
S100B and HMGB1 were increased by the administration of both cobra and viper venoms in male albino mice. 
The venoms may act through the stimulation of arachidonic acid pathway that leads to the generation of ROS 
and cytokines which leads to haemorrhage and tissue injury41,45,46. Tissue injury caused due to snake envenom-
ation could be because of different mechanism. One of the mechanisms is inflammatory response which entails 
the generation of Hsp70, Hsp90, HMGB1, IL6, vWF and S100b. They are all generated through the arachidonic 
acid pathway. The metabolism of arachidonic acid by lipo-oxygenase or cyclo-oxygenase causes the release of 
pro-inflammatory marker proteins. Presence of PLA2 in viper venom helps in the conversion of the phospholipids 
to arachidonic acid which causes release of cytokines and leukotrienes25,47,48. The TiO2-NPs inhibits the produc-
tion of sterile inflammatory proteins in venom-induced experimental rodents. The fold of protection is higher 
in case of viper venom than the cobra venom may be because of the difference in PLA2 concentration. PLA2 is 
Figure 4. Possible mechanism of action of TiO2 [TiO2–in (inhibition)]. Snake venom-induced necrosis, 
haemorrhagic, lethal and inflammation and its neutralization by TiO2-NPs.
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higher in viper venom than the cobra venom. Further study may provide new biological probes in the treatments 
of snakebite. TiO2-NPs have shown better results in in vitro than in in vivo experiments. Our present investigation 
showed that the TiO2-NPs is effective against venom-induced pathophysiological conditions and could be taken 
as a potential antidote. The present work may be helpful to treat victims of snakebite especially in rural parts of 
India where availability of antiserum is limited. We are engage to explore the mechanism of venom inhibition by 
TiO2-NPs as a potential therapeutic agent against snake envenomation49,50.
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